WASHINGTON, Nov. 12, 2024
Detection of Alzheimer's disease in its early stages is crucial to initiating treatment
WASHINGTON, Nov. 12, 2024 /PRNewswire/ -- The availability of amyloid-reducing therapies now makes detection of Alzheimer's disease in its early stages critical, according to new expert-led Clinical Proceedings white paper from the Clinical Neurological Society of America.
Advertisement
Alzheimer's disease is the most common cause of dementia in the elderly and is characterized by abnormal deposits of amyloid-beta and tau proteins in the brain. This disease has a devastating impact on a person's memory, cognition, behavior and activities of daily living. Although the diagnosis is often made clinically based on symptoms, the field is moving toward a biological diagnosis that permits disease detection in earlier stages. Biomarkers can be evaluated via imaging or in body tissues or fluids such as blood.
Advertisement
The paper, Alzheimer's Disease: Understanding its Devastating Impact and Trend Toward Biological Diagnosis, is authored by five clinical neurologists and radiologist and calls for:
Expert Panelists:
Statement from expert panel chair Marissa Natelson Love, MD:"The trend toward more significant use of biomarkers to detect Alzheimer's disease will help us get patients on therapy earlier in the disease before it progresses, improving their quality of life and that of their family and caregivers."
Learn more: "Alzheimer's Disease: Understanding its Devastating Impact and Trend Toward Biological Diagnosis."
The Clinical Neurological Society of America, a non-profit 501(c)(6), is a nationwide organization of neurology clinicians with a mission to improve clinical practice and patient care through education and thought leadership.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurologists-describe-early-detection-of-alzheimers-disease-as-critical-for-new-treatments-302303053.html
SOURCE Clinical Neurological Society of America
